NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

NCT00460486

CompletedPhase 3

Sponsor: Pfizer

Conditions: Encephalitis, Tick-Borne

Interventions: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Countries: Poland

The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml in two age strata (stratum A: 16 to 49 years, stratum B: \> 50 years), with the first and second vaccinations being administered according to a rapid immunization schedule (12 ± 2 days apart). The third vaccination will be administered approximately 6 months after the first dose.

Eligibility overview

Sex: ALL

Age: 16 Years to

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

Male and female subjects will be eligible for participation in this study if they:

* Understand the nature of the study, agree to its provisions and provide written informed consent (assent if the subjects is under 18 years of age);
* Provide the written informed consent of their parents / legal guardian (if the subject is under 18 years of age);
* Are aged \>= 16 years (from the 16th birthday) at screening;
* Are clinically healthy, (i.e. the physician would have no reservations vaccinating with FSME-IMMUN 0.5 ml outside the scope of a clinical trial);
* Have a negative pregnancy test result at the first medical examination (if female and capable of bearing children);
* Agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children);
* Agree to keep a Subject Diary.

Exclusion Criteria:

Subjects will be excluded from participation in this study if they:

* Have a history of any previous tick-borne encephalitis (TBE) vaccination;
* Have a history of TBE infection;
* Have a history of infection with or vaccination against other flaviviruses (e.g. dengue fever, yellow fever, Japanese B-encephalitis);
* Have a history of allergic reactions, in particular to one of the components of the vaccine;
* Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids) that can be expected to influence immunological functions;
* Have a known or suspected problem with drug or alcohol abuse (\> 4 liters wine / week or equivalent level of other alcoholic beverages);
* Have donated blood or plasma within 30 days of study entry;
* Have received a blood transfusion or immunoglobulins within 30 days of study entry;
* Are known to be HIV positive (an HIV test is not required specifically for the purpose of this study);
* Are simultaneously participating in another clinical trial including administration of an investigational product;
* Have participated in any other clinical study within six weeks prior to study entry;
* Are pregnant or breastfeeding (if female);
* Are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the investigator.
* Have received any other vaccination within two weeks prior to study entry.
Locations (4)
  • Krakow, Poland
  • Olsztyn, Poland
  • Olsztyn, Poland
  • Olsztyn, Poland